sumatriptan has been researched along with Anxiety in 3 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'." | 6.75 | Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. ( Allen, A; Bernardi, S; Hollander, E; Pallanti, S, 2010) |
| "In order to investigate the plausible association of migraine recurrence with anxiety and depressive symptoms, a multicentre, randomized, double-blind, placebo-controlled, crossover clinical trial was conducted using sumatriptan as a vehicle drug." | 5.14 | Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. ( Charmoussi, S; Doitsini, S; Georgiadis, G; Kodounis, A; Mitsikostas, DD; Thomas, A; Vikelis, M; Xifaras, M; Zaglis, D, 2010) |
| "Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'." | 2.75 | Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. ( Allen, A; Bernardi, S; Hollander, E; Pallanti, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mason, BN | 1 |
| Kaiser, EA | 1 |
| Kuburas, A | 1 |
| Loomis, MM | 1 |
| Latham, JA | 1 |
| Garcia-Martinez, LF | 1 |
| Russo, AF | 1 |
| Pallanti, S | 1 |
| Bernardi, S | 1 |
| Allen, A | 1 |
| Hollander, E | 1 |
| Mitsikostas, DD | 1 |
| Vikelis, M | 1 |
| Kodounis, A | 1 |
| Zaglis, D | 1 |
| Xifaras, M | 1 |
| Doitsini, S | 1 |
| Georgiadis, G | 1 |
| Thomas, A | 1 |
| Charmoussi, S | 1 |
2 trials available for sumatriptan and Anxiety
| Article | Year |
|---|---|
Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan.
Topics: Adult; Anxiety; Case-Control Studies; Cross-Over Studies; Double-Blind Method; Female; Gambling; Hum | 2010 |
Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial.
Topics: Adult; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Humans; Male; Middle Ag | 2010 |
1 other study available for sumatriptan and Anxiety
| Article | Year |
|---|---|
Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.
Topics: Animals; Anxiety; Calcitonin Gene-Related Peptide; Darkness; Female; Injections, Intraperitoneal; Li | 2017 |